NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

exwannabe,

This is a very correct assessment which is why I did not say it would not be approved, however, no one wants to use a product with a potential to be less effective as a consequence of different type of administration. The broad range of other adverse events were also different and some categories strikingly so which is likely because of different types of administration.
I get what you are saying about non inferiority range but as you have seen with L, improvements have been made since the Phase 3 and those are translating into improved outcomes not worse or technically non inferior.
The other issue is that if something like these results came out for L there would be a whole slew of attacks by the bears about this. Just sayin; ). Best wishes.